Metyrosine
Demser, Metyrosine (metyrosine) is a small molecule pharmaceutical. Metyrosine was first approved as Demser on 1982-01-01. It is used to treat pheochromocytoma in the USA. The pharmaceutical is active against tyrosine 3-monooxygenase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Demser, Metyrosine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metyrosine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEMSER | Bausch Health Companies | N-017871 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| demser | New Drug Application | 2021-07-01 |
| metyrosine | ANDA | 2023-01-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pheochromocytoma | — | D010673 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leiomyoma | D007889 | HP_0000131 | D25 | — | — | — | 1 | — | 1 |
| Myofibroma | D047708 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 2 | — | — | — | 2 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Digeorge syndrome | D004062 | — | D82.1 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | 1 | — | — | — | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | 1 | — | — | — | 1 |
| Primitive neuroectodermal tumors peripheral | D018241 | — | — | — | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 4 | 4 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | — | 2 | 2 |
| Bulimia | D002032 | — | F50.2 | — | — | — | — | 1 | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | — | — | — | 1 | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | — | — | — | 1 | 1 |
| Reward | D012201 | — | — | — | — | — | — | 1 | 1 |
| Thoracic neoplasms | D013899 | — | — | — | — | — | — | 1 | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | — | — | 1 | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metyrosine |
| INN | metirosine |
| Description | Alpha-methyl-L-tyrosine is an L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. It has a role as an antihypertensive agent and an EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor. It is a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@](N)(Cc1ccc(O)cc1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 672-87-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200862 |
| ChEBI ID | 6912 |
| PubChem CID | 441350 |
| DrugBank | DB00765 |
| UNII ID | DOQ0J0TPF7 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 296 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
53 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use